0001144204-19-034585.txt : 20190712 0001144204-19-034585.hdr.sgml : 20190712 20190712163219 ACCESSION NUMBER: 0001144204-19-034585 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20190712 DATE AS OF CHANGE: 20190712 EFFECTIVENESS DATE: 20190712 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Akari Therapeutics Plc CENTRAL INDEX KEY: 0001541157 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 981034922 STATE OF INCORPORATION: X0 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-344207 FILM NUMBER: 19953304 BUSINESS ADDRESS: STREET 1: 24 WEST 40TH STREET STREET 2: 8TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10018 BUSINESS PHONE: (646) 350-0702 MAIL ADDRESS: STREET 1: 24 WEST 40TH STREET STREET 2: 8TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10018 FORMER COMPANY: FORMER CONFORMED NAME: Celsus Therapeutics Plc. DATE OF NAME CHANGE: 20130621 FORMER COMPANY: FORMER CONFORMED NAME: Morria Biopharmaceuticals PLC DATE OF NAME CHANGE: 20120201 D 1 primary_doc.xml X0708 D LIVE 0001541157 Akari Therapeutics Plc 75/76 WIMPOLE STREET LONDON X0 UNITED KINGDOM W1G 9RT +44 20 8004 0270 UNITED KINGDOM None Celsus Therapeutics Plc. Morria Biopharmaceuticals PLC Corporation true Clive Richardson c/o Akari Therapeutics, PLC 75/76 Wimpole Street London X0 UNITED KINGDOM W1G 9RT Executive Officer Director Dov Elefant c/o Akari Therapeutics, PLC 75/76 Wimpole Street London X0 UNITED KINGDOM W1G 9RT Executive Officer Director Ray Prudo c/o Akari Therapeutics, PLC 75/76 Wimpole Street London X0 UNITED KINGDOM W1G 9RT Executive Officer Director James Hill c/o Akari Therapeutics, PLC 75/76 Wimpole Street London X0 UNITED KINGDOM W1G 9RT Director Stuart Ungar c/o Akari Therapeutics, PLC 75/76 Wimpole Street London X0 UNITED KINGDOM W1G 9RT Director David Byrne c/o Akari Therapeutics, PLC 75/76 Wimpole Street London X0 UNITED KINGDOM W1G 9RT Director Donald Williams c/o Akari Therapeutics, PLC 75/76 Wimpole Street London X0 UNITED KINGDOM W1G 9RT Director Michael Grissinger c/o Akari Therapeutics, PLC 75/76 Wimpole Street London X0 UNITED KINGDOM W1G 9RT Director Peter Feldschreiber c/o Akari Therapeutics, PLC 75/76 Wimpole Street London X0 UNITED KINGDOM W1G 9RT Director Biotechnology Decline to Disclose 06b false 2019-06-28 false true true false 0 Paulson Investment Company, LLC 5670 None None 2141 W. NORTH AVE. 2ND FLOOR CHICAGO IL ILLINOIS 60647 AL ALABAMA AZ ARIZONA CA CALIFORNIA CO COLORADO CT CONNECTICUT FL FLORIDA IL ILLINOIS KS KANSAS MD MARYLAND MA MASSACHUSETTS MI MICHIGAN MN MINNESOTA NV NEVADA NH NEW HAMPSHIRE NJ NEW JERSEY NM NEW MEXICO NY NEW YORK OH OHIO PA PENNSYLVANIA TX TEXAS VA VIRGINIA WA WASHINGTON true 4499945 4499945 0 The warrants and shares underlying the warrants, the subject matter of this Form D were issued in connection with an offering of (i) 2,368,392 ADSs issued in a registered direct offering, and (ii) unregistered warrants to purchase 1,184,213 ADSs. false 45 337496 0 Paulson Investment Company, LLC is also entitled to expense reimbursement of up to $50,000, a non-accountable expense allowance of $10,000 and warrants to purchase an aggregate of 177,629 ADSs exercisable at $2.85 per ADS for five years. 0 Issuer expects to use proceeds from the offering to fund its ongoing research and clinical development efforts and for working capital and general corporate purposes. false Akari Therapeutics Plc /s/ Clive Richardson Clive Richardson Interim Chief Executive Officer and Chief Operating Officer 2019-07-12